AMRX Q4 2023 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$617M+1.2% YoY

Gross Profit

$225M36.5% margin

Operating Income

$14M2.3% margin

Net Income

-$99M-16.0% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

-0.5%

Cash Flow

Operating Cash Flow

$136M

Free Cash Flow

$104M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$3.5B

Total Liabilities

$3.4B

Stockholders' Equity

$20M

Cash & Equivalents

$92M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$617M	$610M	+1.2%
Gross Profit	$225M	$215M	+4.7%
Operating Income	$14M	$36M	-60.6%
Net Income	-$99M	-$4M	-2176.7%

Revenue Segments

Generics Segment

$754M100%